MarketCap
Facebook
X
TelegramAnnual report 2024
added 02-14-2026
AstraZeneca PLC Cash and Cash Equivalents 2011-2026 | AZN
Annual Cash and Cash Equivalents AstraZeneca PLC
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.49 B | 5.84 B | 6.17 B | 6.33 B | 7.83 B | 5.37 B | 4.83 B | 3.32 B | 5.02 B | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.83 B | 3.32 B | 5.58 B |
Quarterly Cash and Cash Equivalents AstraZeneca PLC
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 6.33 B | - | 15.6 B | - | 7.83 B | - | 5.67 B | - | 5.37 B | - | 5.43 B | - | 4.83 B | - | 2.98 B | - | 3.32 B | - | 5.24 B | - | 5.02 B | - | - | - | 6.24 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 15.6 B | 2.98 B | 6.15 B |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M |  USA |
 |
Autolus Therapeutics plc
AUTL
|
240 M | $ 1.68 | 2.44 % | $ 429 M |  Britain |
 |
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | USA |
 |
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | USA |
 |
Kamada Ltd.
KMDA
|
78.4 M | $ 8.81 | 1.73 % | $ 260 M |  Israel |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M |  France |
 |
Adagene
ADAG
|
75.2 M | $ 3.26 | 0.62 % | $ 183 M | China |
 |
Alterity Therapeutics Limited
ATHE
|
34.8 M | $ 3.28 | -2.62 % | $ 7.89 B |  Australia |
 |
Evogene Ltd.
EVGN
|
15.3 M | $ 0.81 | -9.28 % | $ 27.9 M | Israel |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
830 K | - | -19.68 % | $ 18.4 M | Canada |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |
 |
Aptorum Group Limited
APM
|
3.5 M | $ 0.79 | -1.29 % | $ 4.31 M | China |
 |
Alpine Immune Sciences
ALPN
|
13.4 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
118 M | - | 4.14 % | $ 49.1 M | USA |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
371 K | $ 0.88 | -1.43 % | $ 442 M | Israel |
 |
Allena Pharmaceuticals
ALNA
|
30 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | USA |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | USA |
 |
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
Aptose Biosciences
APTO
|
6.15 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aravive
ARAV
|
53.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Ascendis Pharma A/S
ASND
|
616 M | $ 224.42 | -2.52 % | $ 5 B |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
220 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
37.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
AVROBIO
AVRO
|
98 M | - | 1083.1 % | $ 745 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
103 M | $ 4.13 | 0.12 % | $ 352 M | USA |
 |
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
345 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aytu BioScience
AYTU
|
31 M | $ 2.36 | 2.27 % | $ 14.8 M | USA |
 |
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
4.88 M | - | 17.91 % | $ 11.1 M | USA |
 |
Brickell Biotech
BBI
|
10.9 M | - | -5.38 % | $ 6.06 M | USA |
 |
Codexis
CDXS
|
19.3 M | $ 1.17 | -0.85 % | $ 85.9 M | USA |
 |
Athira Pharma
ATHA
|
48.4 M | - | - | $ 269 M | USA |
 |
BioNTech SE
BNTX
|
9.76 B | $ 110.12 | -0.28 % | $ 27.2 B | Germany |
 |
Amneal Pharmaceuticals
AMRX
|
111 M | $ 14.49 | -0.75 % | $ 4.48 B | USA |
 |
AIkido Pharma
AIKI
|
4.08 M | - | 1.93 % | $ 17.4 M | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |